Edmund Optics: Minimize Ultrafast Pulse Spreading with Low Group Delay Dispersion Optics

Edmund Optics, a leading global manufacturer and supplier of optical components, now internally manufactures short pulse optics with low group delay dispersion (GDD) out of Edmund Optics Florida, formerly known as Quality Thin Films (QTF). These optics minimize chromatic aberration and pulse spreading in ultrafast laser systems, resulting in higher peak powers.

Minimize Ultrafast Pulse Spreading with Low Group Delay Dispersion Optics
Edmund Optics®, leading global manufacturer and supplier of optical components, now internally manufactures short pulse optics with low group delay dispersion (GDD) out of Edmund Optics Florida, formerly known as Quality Thin Films (QTF).

Before being acquired by Edmund Optics, Quality Thin Films (QTF), a leading laser optics manufacturer, had the ability to design and coat low GDD optics, though they lacked the metrology required to verify the specifications. Customer feedback showed that the optics performed well, but this could not be confirmed in-house. Edmund Optics uses white light interferometers and an in-house ultrafast laser to measure GDD, allowing measurement of these challenging optics to verify their performance in real environments.

Low GDD optics from Edmund Optics Florida are measured before they are shipped, guaranteeing GDD specifications from 250 to 3,200 nm within +- 10 fs². Whether you require low GDD mirrors, filters, or other ultrafast optics, Edmund Optics has the manufacturing and metrology technology to create a solution for you.

Edmund Optics Florida excels in manufacturing a wide variety of laser optics including laser crystals, high laser-induced damage threshold optics, and now low GDD optics.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.